Form 4: Cogent Biosciences Director Todd Shegog Granted Significant Stock Options

Cogent Biosciences Director Todd Shegog was granted 44,700 stock options with an exercise price of $5.64, aligning his interests with shareholder value.

Summary

• Todd Shegog, a Director of Cogent Biosciences, Inc. (COGT), acquired 44,700 stock options.
• The transaction date for the option grant was June 4, 2025.
• Each stock option has an exercise price of $5.64.
• The options are for Common Stock and will expire on June 4, 2035.
• These stock options will vest in full upon the earlier of the first anniversary of the grant date (June 4, 2026) or the date of the 2026 Annual Meeting of Stockholders.
• Following this transaction, Todd Shegog beneficially owns 44,700 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event and does not indicate any negative operational or financial news.

Positives

• The grant of stock options to Director Todd Shegog aligns his financial interests with the long-term performance and shareholder value of Cogent Biosciences.
• The vesting schedule encourages continued commitment and performance from the director over the specified period.

Negatives

• The document does not contain any explicitly negative information regarding the company's performance or outlook; it is a routine insider transaction disclosure.

Risks

• The document notes that intentional misstatements or omissions of facts constitute Federal Criminal Violations, as per 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Future Outlook

The vesting schedule for the granted stock options indicates a future alignment of the director's incentives with the company's performance, as the options will vest upon the earlier of the first anniversary of the grant date or the 2026 Annual Meeting of Stockholders.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to incentivize long-term value creation and align leadership interests with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation within the biotechnology and broader corporate sectors, designed to align the interests of board members with shareholder returns.
• The vesting schedule, tied to either a specific anniversary or the next annual meeting, is also a common mechanism to ensure continued engagement and performance.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Management: This compensation structure reinforces the importance of long-term strategic decisions and company growth.

Next Steps

• The stock options will vest in full upon the earlier of June 4, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Todd Shegog may choose to exercise these options at any time after vesting and before the expiration date of June 4, 2035, subject to company policy and market conditions.

Key Dates

Keywords

Cogent Biosciences, COGT, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership